/**/ RNS Number : 8681K IQ-AI Limited 05 November 2024 November 5, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) New Patent Application, Trading Update and Commencement of discussions with potential phase 2 partners IQ-AI (LSE: IQAI) Imaging Biometrics (“IB”) has filed a provisional patent application with the United States Patent and Trademark
/**/ RNS Number : 2550I IQ-AI Limited 15 October 2024 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which
/**/ RNS Number : 0933I IQ-AI Limited 14 October 2024 TR-1: Standard form for notification of major holdings 1. IssuerDetails ISIN JE00BD4H0R42 Issuer Name IQ-AI LIMITED UK or Non-UK Issuer Non-UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Free Association
/**/ RNS Number : 0916I IQ-AI Limited 14 October 2024 PDMR dealing and TR1 announcement Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Trevor Brown 2 Reason for the notification a)
/**/ RNS Number : 8995H IQ-AI Limited 11 October 2024 11 October 2024 IQ-AI Limited IQ-AI Limited (“IQ-AI” or the “Company”) Acquisition of Interest by Braveheart Investment Group IQ-AI Limited (the “Company” or “IQ-AI”), the parent company of Wisconsin-based Imaging Biometrics, LLC (“IB”), which is focused on delivering quantitative imaging platforms and therapeutics that
/**/ RNS Number : 3064A IQ-AI Limited 13 August 2024 13 August 2024 IQ-AI Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2024 The Board of IQ-AI Ltd is pleased to announce the Company’s half yearly report for the period ended 30 June 2024. For further information,
/**/ RNS Number : 7858T IQ-AI Limited 25 June 2024 June 25, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Opens Expanded Access Program New cancer treatment with the potential to slow brain tumor growth is now available to patients in the US with relapsed/refractory histologic or molecular glioblastoma Imaging Biometrics, LLC
/**/ RNS Number : 3271Q IQ-AI Limited 29 May 2024 IQ-AI Limited (“IQ-AI” or the “Company”) Result of AGM IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed. For information, the proxy votes received prior to the meeting were
/**/ RNS Number : 5528P IQ-AI Limited 23 May 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Major East Coast Health System Chooses IB Nimble for Their Brain Metastases Program of Excellence Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), today announces that a leading cancer centre located